Geisinger, Merck collaborate for patient adherence

Geisinger Health System and pharmaceutical company Merck will enter into a new multi-year collaboration designed to improve patient health outcomes by focusing on shared decision making between patients and physicians and improved patient adherence.

Teams from Danville, Pa.-based Geisinger and Whitehouse Station, N.J.-based Merck will work together to improve patient adherence, increase the role of patients in making decisions to help manage their conditions, share information among extended care teams and improve clinical care processes, according to a statement from the organizations.

The first tool being developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome, a clustering of various risk factors that puts an individual at risk of developing type 2 diabetes and cardiovascular disease.

The web application and other care management tools Merck and Geisinger develop will initially be tested within the Geisinger system, they added. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.